Quest Extends Tender Offer for Celera Shares for Final Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today extended its tender offer for Celera's shares to May 10, 5 p.m. EDT.

The offering, made in connection with Quest's $671 million purchase of Celera, is being made through Quest's wholly owned subsidiary, Spark Acquisition, and will not be extended further, Quest said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.